RxDoctor Payments Data

Micalove Raphael, NP

Family · West Palm Beach, FLNPI 1386415867

Payments from drug & device makers

$1,105in general payments, 2019–2025

Across 47 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$259
  • Exact Sciences$236
  • Bayer$120
  • AstraZeneca$115
  • Boehringer Ingelheim$96
  • Lilly USA, LLC$64
  • plus $214 from 6 others

What the payments were for

  • Food & beverage$1,06797%
  • Education$383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,105 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$3,210
Medicare patients
17
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol40$38,179
JardianceEmpagliflozin28$28,682
EliquisApixaban29$22,086
TrulicityDulaglutide14$15,497
OzempicSemaglutide12$13,124
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,855
Albuterol Sulfate HfaAlbuterol Sulfate80$2,733
Lidocaine27$1,995
Atorvastatin Calcium134$1,784
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$1,702
Humalog Kwikpen U-100Insulin Lispro14$1,411
Diclofenac Sodium37$1,003
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen92$816
Gabapentin55$784
EndocetOxycodone Hcl/Acetaminophen61$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$115$38,17940 claims
Boehringer IngelheimJardiance$96$28,68228 claims
Lilly USA, LLCTrulicity$64$15,49714 claims
Novo NordiskOzempic$259$13,12412 claims
GSKTrelegy Ellipta$39$12,85517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →